
Please try another search
StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. The company develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy. Its pre-clinical stage products include PJ2 and PJ3 to treat multiple tissue damage disease; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. StemRIM was incorporated in 2006 and is based in Ibaraki, Japan.
Name | Age | Since | Title |
---|---|---|---|
Katsuto Tamai | - | - | Director |
Masatsune Okajima | 56 | 2019 | President, CEO & Representative Director |
Noriko Sawai | 52 | 2019 | Independent Outside Director |
Akihiro Mizukami | 69 | 2019 | External Auditor |
Yoji Kudo | 77 | 2017 | External Auditor |
Yoichiro Shimada | 70 | 2019 | External Auditor |
Katsuto Tamai | 65 | 2022 | Founder, Chief Scientific Officer & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review